Carregant...
Antibodies to watch in 2015
The commercial pipeline of recombinant antibody therapeutics is robust and dynamic. As of early December 2014, a total of 6 such products (vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab) were granted first marketing approvals in 2014. As discussed in this perspective on...
Guardat en:
| Publicat a: | MAbs |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622967/ https://ncbi.nlm.nih.gov/pubmed/25484055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/19420862.2015.988944 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|